AstraZeneca AB
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference fc9af36b01
Drug names107First applicant · distinct drug namesAcceptance records777First applicant · distinct acceptance numbersUnder-review numbers42First applicant · current under-review listCo-applicant records109Subsequent applicant only · separate count
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/11 06:42.
Drug filings
777 acceptance records as first applicant, grouped into 107 source drug names. Source data as of 2026/11/11 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
No verified English name 1 records · Latest accepted 2026/11/09
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2600309 | Import | 2026/11/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd | CDE ↗ |
No verified English name 17 records · Latest accepted 2026/11/06
Supplement · 7Import · 10
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHB2600164 | Supplement | 2026/11/06 | AstraZeneca AB; Patheon France | CDE ↗ |
| JXHB2600163 | Supplement | 2026/11/06 | AstraZeneca AB; Patheon France | CDE ↗ |
| JXHB2600162 | Supplement | 2026/11/06 | AstraZeneca AB; Patheon France | CDE ↗ |
| JXHL2600482 | Import | 2026/11/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600481 | Import | 2026/11/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600035 | Import | 2026/02/07 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600034 | Import | 2026/02/07 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600023 | Import | 2026/01/21 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600022 | Import | 2026/01/21 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600021 | Import | 2026/01/21 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600020 | Import | 2026/01/21 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHB2500104 | Supplement | 2025/08/13 | AstraZeneca AB; Patheon France | CDE ↗ |
| JXHB2500103 | Supplement | 2025/08/13 | AstraZeneca AB; Patheon France | CDE ↗ |
| JXHB2400167 | Supplement | 2024/10/17 | AstraZeneca AB | CDE ↗ |
| JXHB2400166 | Supplement | 2024/10/17 | AstraZeneca AB | CDE ↗ |
| JXHL2300292 | Import | 2023/11/20 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2300291 | Import | 2023/11/20 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 12 records · Latest accepted 2026/11/06
Supplement · 1Import · 8Not stated by source · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYSB2600312 | Supplement | 2026/11/06 | AstraZeneca AB; Amgen Manufacturing Limited LLC | CDE ↗ |
| JXSS2600101 | Import | 2026/10/30 | AstraZeneca AB; Amgen Manufacturing Limited LLC; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXSS2600100 | Import | 2026/10/30 | AstraZeneca AB; Amgen Manufacturing Limited LLC; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JTS2600149 | Not stated by source | 2026/09/21 | AstraZeneca AB; Shanghai Hong Cheng Pharma Co., Ltd. romanized | CDE ↗ |
| JTS2600148 | Not stated by source | 2026/09/21 | AstraZeneca AB; Shanghai Hong Cheng Pharma Co., Ltd. romanized | CDE ↗ |
| JTS2500144 | Not stated by source | 2025/11/26 | AstraZeneca AB; Qi Lu Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| JXSL2500184 | Import | 2025/09/26 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXSL2500123 | Import | 2025/07/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXSS2500020 | Import | 2025/02/25 | AstraZeneca AB; Amgen Manufacturing Limited LLC; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXSS2500019 | Import | 2025/02/25 | AstraZeneca AB; Amgen Manufacturing Limited LLC; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXSS2400103 | Import | 2024/11/22 | AstraZeneca AB; Amgen Manufacturing Limited LLC; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXSS2400102 | Import | 2024/11/22 | AstraZeneca AB; Amgen Manufacturing Limited LLC; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
No verified English name 37 records · Latest accepted 2026/11/03
Import · 27Supplement · 10
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2600294 | Import | 2026/11/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2600293 | Import | 2026/11/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2600288 | Import | 2026/10/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2600287 | Import | 2026/10/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2600284 | Import | 2026/10/23 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2600283 | Import | 2026/10/23 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2600197 | Supplement | 2026/10/21 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2600196 | Supplement | 2026/10/21 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2600156 | Supplement | 2026/08/20 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2600155 | Supplement | 2026/08/20 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2600141 | Supplement | 2026/08/12 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2600140 | Supplement | 2026/08/12 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2600054 | Import | 2026/02/24 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2600053 | Import | 2026/02/24 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2600027 | Supplement | 2026/02/13 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2600026 | Supplement | 2026/02/13 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2500199 | Import | 2025/10/15 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500198 | Import | 2025/10/15 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500186 | Import | 2025/09/26 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500185 | Import | 2025/09/26 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500160 | Import | 2025/08/27 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500159 | Import | 2025/08/27 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500158 | Import | 2025/08/26 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500157 | Import | 2025/08/26 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500154 | Import | 2025/08/14 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500153 | Import | 2025/08/14 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500152 | Import | 2025/08/14 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500151 | Import | 2025/08/14 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500150 | Import | 2025/08/14 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500139 | Import | 2025/08/05 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500138 | Import | 2025/08/05 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2500035 | Supplement | 2025/05/10 | AstraZeneca AB; Vetter Development Services USA Inc. | CDE ↗ |
| JXSB2400159 | Supplement | 2024/11/28 | AstraZeneca AB; Vetter Development Services USA Inc. | CDE ↗ |
| JXSL2400168 | Import | 2024/09/14 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400163 | Import | 2024/09/05 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400162 | Import | 2024/09/05 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2300229 | Import | 2023/12/15 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 5 records · Latest accepted 2026/11/03
Import · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2600292 | Import | 2026/11/03 | AstraZeneca AB; AstraZeneca Global ll&U (China) Co. Ltd. | CDE ↗ |
| JXSL2500210 | Import | 2025/11/06 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500016 | Import | 2025/01/21 | AstraZeneca AB; AstraZeneca Global ll&U (China) Co. Ltd. | CDE ↗ |
| JXSL2500015 | Import | 2025/01/21 | AstraZeneca AB; AstraZeneca Global ll&U (China) Co. Ltd. | CDE ↗ |
| JXSL2400149 | Import | 2024/08/17 | AstraZeneca AB; AstraZeneca Global ll&U (China) Co. Ltd. | CDE ↗ |
No verified English name 4 records · Latest accepted 2026/10/28
Import · 3Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2600286 | Import | 2026/10/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2600171 | Supplement | 2026/09/07 | AstraZeneca AB; Simtra Deutschland GmbH | CDE ↗ |
| JXSL2500176 | Import | 2025/09/16 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500175 | Import | 2025/09/16 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 3 records · Latest accepted 2026/10/15
Supplement · 2Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSB2600193 | Supplement | 2026/10/15 | AstraZeneca AB; Simtra Deutschland GmbH | CDE ↗ |
| JXSB2600172 | Supplement | 2026/09/08 | AstraZeneca AB; Simtra Deutschland GmbH | CDE ↗ |
| JXSL2400183 | Import | 2024/09/27 | AstraZeneca AB; AstraZeneca Investment (China) Co. Limited | CDE ↗ |
No verified English name 4 records · Latest accepted 2026/10/12
Supplement · 3Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600546 | Supplement | 2026/10/12 | AstraZeneca AB | CDE ↗ |
| JYHB2600093 | Supplement | 2026/02/10 | AstraZeneca AB | CDE ↗ |
| JXHS2600023 | Import | 2026/02/10 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHB2500491 | Supplement | 2025/09/18 | AstraZeneca AB | CDE ↗ |
No verified English name 4 records · Latest accepted 2026/10/08
Import · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2600437 | Import | 2026/10/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600436 | Import | 2026/10/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600223 | Import | 2026/06/23 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600222 | Import | 2026/06/23 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 4 records · Latest accepted 2026/10/08
Import · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2600264 | Import | 2026/10/08 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXSL2600263 | Import | 2026/10/08 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXSL2600086 | Import | 2026/03/27 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXSS2500109 | Import | 2025/08/20 | AstraZeneca AB; AstraZeneca Nijmegen B.V.; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
No verified English name 7 records · Latest accepted 2026/09/24
Import · 4Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2600417 | Import | 2026/09/24 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHB2500064 | Supplement | 2025/05/10 | AstraZeneca AB | CDE ↗ |
| JXHB2300086 | Supplement | 2023/05/25 | AstraZeneca AB | CDE ↗ |
| JXHB2300085 | Supplement | 2023/05/25 | AstraZeneca AB | CDE ↗ |
| JXHL2200064 | Import | 2022/03/22 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2200063 | Import | 2022/03/22 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2200062 | Import | 2022/03/22 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
Osimertinib Mesylate Tablets 54 records · Latest accepted 2026/09/04
Supplement · 20Import · 24Import re-registration · 8Not stated by source · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHB2600125 | Supplement | 2026/09/04 | AstraZeneca AB | CDE ↗ |
| JXHB2600124 | Supplement | 2026/09/04 | AstraZeneca AB | CDE ↗ |
| JXHL2600355 | Import | 2026/08/19 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2600354 | Import | 2026/08/19 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYHB2600457 | Supplement | 2026/08/12 | AstraZeneca AB | CDE ↗ |
| JYHB2600456 | Supplement | 2026/08/12 | AstraZeneca AB | CDE ↗ |
| JYHB2600356 | Supplement | 2026/06/30 | AstraZeneca AB | CDE ↗ |
| JYHB2600355 | Supplement | 2026/06/30 | AstraZeneca AB | CDE ↗ |
| JYHZ2500224 | Import re-registration | 2025/10/14 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHZ2500223 | Import re-registration | 2025/10/14 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHZ2500222 | Import re-registration | 2025/10/14 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHZ2500221 | Import re-registration | 2025/10/14 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2500297 | Import | 2025/09/24 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2500296 | Import | 2025/09/24 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHS2500108 | Import | 2025/09/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHS2500107 | Import | 2025/09/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JTH2500009 | Not stated by source | 2025/02/09 | AstraZeneca AB; He Ji Huang Pu Pharmaceuticals (Shanghai) Co., Ltd. romanized | CDE ↗ |
| JXHL2400258 | Import | 2024/10/25 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2400257 | Import | 2024/10/25 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHB2400369 | Supplement | 2024/07/17 | AstraZeneca AB | CDE ↗ |
| JYHB2400368 | Supplement | 2024/07/17 | AstraZeneca AB | CDE ↗ |
| JXHS2400042 | Import | 2024/06/21 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHS2400041 | Import | 2024/06/21 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHB2400005 | Supplement | 2024/01/04 | AstraZeneca AB | CDE ↗ |
| JYHB2400004 | Supplement | 2024/01/04 | AstraZeneca AB | CDE ↗ |
| JXHL2300322 | Import | 2023/12/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300321 | Import | 2023/12/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300320 | Import | 2023/12/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2300319 | Import | 2023/12/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHS2300087 | Import | 2023/09/21 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHS2300086 | Import | 2023/09/21 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHB2300486 | Supplement | 2023/08/29 | AstraZeneca AB | CDE ↗ |
| JYHB2300485 | Supplement | 2023/08/29 | AstraZeneca AB | CDE ↗ |
| JYHB2300132 | Supplement | 2023/02/21 | AstraZeneca AB | CDE ↗ |
| JYHB2300131 | Supplement | 2023/02/21 | AstraZeneca AB | CDE ↗ |
| JTH2300035 | Not stated by source | 2023/02/11 | AstraZeneca AB; He Ji Huang Pu Pharmaceuticals (Shanghai) Co., Ltd. romanized | CDE ↗ |
| JXHB2200040 | Supplement | 2022/03/24 | AstraZeneca AB | CDE ↗ |
| JXHB2200039 | Supplement | 2022/03/24 | AstraZeneca AB | CDE ↗ |
| JYHB2101572 | Supplement | 2021/12/09 | AstraZeneca AB | CDE ↗ |
| JYHB2101571 | Supplement | 2021/12/09 | AstraZeneca AB | CDE ↗ |
| JXHL2101261 | Import | 2021/11/26 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2101260 | Import | 2021/11/26 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2101219 | Import | 2021/10/28 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2101218 | Import | 2021/10/28 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2101016 | Import | 2021/04/26 | AstraZeneca AB; Astrazeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2101015 | Import | 2021/04/26 | AstraZeneca AB; Astrazeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHZ2100528 | Import re-registration | 2021/04/23 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYHZ2100527 | Import re-registration | 2021/04/23 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYHZ2100526 | Import re-registration | 2021/04/23 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYHZ2100525 | Import re-registration | 2021/04/23 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2100068 | Import | 2021/03/03 | AstraZeneca AB | CDE ↗ |
| JXHL2100067 | Import | 2021/03/03 | AstraZeneca AB | CDE ↗ |
| JYHB2100141 | Supplement | 2021/02/20 | AstraZeneca AB | CDE ↗ |
| JYHB2100140 | Supplement | 2021/02/20 | AstraZeneca AB | CDE ↗ |
No verified English name 62 records · Latest accepted 2026/09/01
Supplement · 21Import · 41
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHB2600121 | Supplement | 2026/09/01 | AstraZeneca AB | CDE ↗ |
| JXHB2600120 | Supplement | 2026/09/01 | AstraZeneca AB | CDE ↗ |
| JXHB2600119 | Supplement | 2026/09/01 | AstraZeneca AB | CDE ↗ |
| JXHB2600118 | Supplement | 2026/09/01 | AstraZeneca AB | CDE ↗ |
| JXHB2600097 | Supplement | 2026/07/27 | AstraZeneca AB | CDE ↗ |
| JXHB2600096 | Supplement | 2026/07/27 | AstraZeneca AB | CDE ↗ |
| JXHB2600095 | Supplement | 2026/07/27 | AstraZeneca AB | CDE ↗ |
| JXHB2600094 | Supplement | 2026/07/27 | AstraZeneca AB | CDE ↗ |
| JXHL2600257 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHB2600018 | Supplement | 2026/02/13 | AstraZeneca AB | CDE ↗ |
| JXHB2600017 | Supplement | 2026/02/13 | AstraZeneca AB | CDE ↗ |
| JXHB2600016 | Supplement | 2026/02/13 | AstraZeneca AB | CDE ↗ |
| JXHB2600015 | Supplement | 2026/02/13 | AstraZeneca AB | CDE ↗ |
| JXHL2500389 | Import | 2025/12/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHB2500125 | Supplement | 2025/09/10 | AstraZeneca AB | CDE ↗ |
| JXHB2500124 | Supplement | 2025/09/10 | AstraZeneca AB | CDE ↗ |
| JXHB2500123 | Supplement | 2025/09/10 | AstraZeneca AB | CDE ↗ |
| JXHB2500122 | Supplement | 2025/09/10 | AstraZeneca AB | CDE ↗ |
| JXHL2500119 | Import | 2025/05/20 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2500118 | Import | 2025/05/20 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2500117 | Import | 2025/05/20 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2500116 | Import | 2025/05/20 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2400303 | Import | 2024/12/26 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2400302 | Import | 2024/12/26 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2400301 | Import | 2024/12/26 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2400300 | Import | 2024/12/26 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2400041 | Import | 2024/02/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2400040 | Import | 2024/02/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2400039 | Import | 2024/02/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2400038 | Import | 2024/02/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300300 | Import | 2023/12/02 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300299 | Import | 2023/12/02 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300298 | Import | 2023/12/02 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300297 | Import | 2023/12/02 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300290 | Import | 2023/11/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300289 | Import | 2023/11/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300288 | Import | 2023/11/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300287 | Import | 2023/11/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300275 | Import | 2023/11/07 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300274 | Import | 2023/11/07 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300273 | Import | 2023/11/07 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300272 | Import | 2023/11/07 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300200 | Import | 2023/08/25 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300199 | Import | 2023/08/25 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300198 | Import | 2023/08/25 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300197 | Import | 2023/08/25 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300165 | Import | 2023/07/17 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300164 | Import | 2023/07/17 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300163 | Import | 2023/07/17 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2300162 | Import | 2023/07/17 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHB2300052 | Supplement | 2023/03/16 | AstraZeneca AB | CDE ↗ |
| JXHL2200193 | Import | 2022/07/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2200192 | Import | 2022/07/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2200191 | Import | 2022/07/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2200190 | Import | 2022/07/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHB2200012 | Supplement | 2022/01/19 | AstraZeneca AB | CDE ↗ |
| JXHB2200011 | Supplement | 2022/01/19 | AstraZeneca AB | CDE ↗ |
| JXHB2200010 | Supplement | 2022/01/19 | AstraZeneca AB | CDE ↗ |
| JXHB2200009 | Supplement | 2022/01/19 | AstraZeneca AB | CDE ↗ |
| JXHL2101120 | Import | 2021/07/06 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2101119 | Import | 2021/07/06 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2101118 | Import | 2021/07/06 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
No verified English name 43 records · Latest accepted 2026/08/25
Supplement · 17Import · 26
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSB2600158 | Supplement | 2026/08/25 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2600104 | Supplement | 2026/06/23 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2600141 | Import | 2026/06/12 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2600083 | Supplement | 2026/06/10 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2600073 | Supplement | 2026/05/21 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2600087 | Import | 2026/03/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2600080 | Import | 2026/03/19 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2500163 | Supplement | 2025/12/26 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2500234 | Import | 2025/12/04 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500197 | Import | 2025/10/14 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500193 | Import | 2025/10/10 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500156 | Import | 2025/08/20 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2500074 | Supplement | 2025/07/30 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2500065 | Supplement | 2025/07/10 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2500115 | Import | 2025/07/02 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2500039 | Supplement | 2025/05/16 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2500034 | Supplement | 2025/05/08 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2500044 | Import | 2025/03/26 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500042 | Import | 2025/03/25 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500014 | Import | 2025/01/21 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500007 | Import | 2025/01/11 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500006 | Import | 2025/01/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400252 | Import | 2024/12/26 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2400171 | Supplement | 2024/12/19 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2400130 | Supplement | 2024/10/18 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2400184 | Import | 2024/09/27 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400174 | Import | 2024/09/25 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400173 | Import | 2024/09/25 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400172 | Import | 2024/09/20 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400170 | Import | 2024/09/14 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400165 | Import | 2024/09/12 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JYSB2400166 | Supplement | 2024/07/26 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2400081 | Import | 2024/04/26 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400057 | Import | 2024/03/06 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2300163 | Supplement | 2023/12/14 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2300122 | Supplement | 2023/10/09 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2300145 | Import | 2023/07/29 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2300074 | Import | 2023/04/22 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2300028 | Supplement | 2023/03/21 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2300026 | Supplement | 2023/03/10 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2200193 | Import | 2022/11/05 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2200090 | Supplement | 2022/06/28 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2200026 | Import | 2022/03/14 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 9 records · Latest accepted 2026/08/24
Import · 6Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2600223 | Import | 2026/08/24 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500233 | Import | 2025/12/04 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500103 | Import | 2025/06/21 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2500031 | Supplement | 2025/04/16 | AstraZeneca AB; BSP Pharmaceuticals S.p.A | CDE ↗ |
| JXSL2400251 | Import | 2024/12/26 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400082 | Import | 2024/04/26 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2300024 | Supplement | 2023/03/07 | AstraZeneca AB; BSP Pharmaceuticals S.p.A | CDE ↗ |
| JXSB2300007 | Supplement | 2023/01/08 | AstraZeneca AB; BSP Pharmaceuticals S. p.A | CDE ↗ |
| JXSL2200040 | Import | 2022/03/25 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 12 records · Latest accepted 2026/08/24
Import · 12
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2600362 | Import | 2026/08/24 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600361 | Import | 2026/08/24 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600161 | Import | 2026/05/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600160 | Import | 2026/05/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600159 | Import | 2026/05/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600158 | Import | 2026/05/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2500379 | Import | 2025/12/04 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2500378 | Import | 2025/12/04 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2500182 | Import | 2025/07/12 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2500181 | Import | 2025/07/12 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2500180 | Import | 2025/07/12 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2500179 | Import | 2025/07/12 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 9 records · Latest accepted 2026/08/13
Supplement · 6Not stated by source · 2Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600463 | Supplement | 2026/08/13 | AstraZeneca AB | CDE ↗ |
| JTH2600167 | Not stated by source | 2026/08/05 | AstraZeneca AB; AstraZeneca UK Limited; Kunming Long Jin Pharma Co., Ltd. romanized | CDE ↗ |
| JTH2600107 | Not stated by source | 2026/06/09 | AstraZeneca AB; AstraZeneca UK Limited; Kunming Long Jin Pharma Co., Ltd. romanized | CDE ↗ |
| JYHB2500154 | Supplement | 2025/03/14 | AstraZeneca AB | CDE ↗ |
| JYHZ2400273 | Import re-registration | 2024/10/12 | AstraZeneca AB; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHB2400399 | Supplement | 2024/07/27 | AstraZeneca AB | CDE ↗ |
| JYHB2200506 | Supplement | 2022/09/15 | AstraZeneca AB | CDE ↗ |
| JYHB2200107 | Supplement | 2022/03/03 | AstraZeneca AB | CDE ↗ |
| JYHB2101438 | Supplement | 2021/09/23 | AstraZeneca AB | CDE ↗ |
Ticagrelor Tablets 16 records · Latest accepted 2026/08/13
Supplement · 12Import re-registration · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600465 | Supplement | 2026/08/13 | AstraZeneca AB | CDE ↗ |
| JYHB2600464 | Supplement | 2026/08/13 | AstraZeneca AB | CDE ↗ |
| JYHZ2600021 | Import re-registration | 2026/02/05 | AstraZeneca AB; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2600020 | Import re-registration | 2026/02/05 | AstraZeneca AB; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHB2500156 | Supplement | 2025/03/14 | AstraZeneca AB | CDE ↗ |
| JYHB2500155 | Supplement | 2025/03/14 | AstraZeneca AB | CDE ↗ |
| JYHB2400401 | Supplement | 2024/07/27 | AstraZeneca AB | CDE ↗ |
| JYHB2400400 | Supplement | 2024/07/27 | AstraZeneca AB | CDE ↗ |
| JYHB2200505 | Supplement | 2022/09/15 | AstraZeneca AB | CDE ↗ |
| JYHB2200504 | Supplement | 2022/09/15 | AstraZeneca AB | CDE ↗ |
| JYHB2200106 | Supplement | 2022/03/01 | AstraZeneca AB | CDE ↗ |
| JYHB2200105 | Supplement | 2022/03/01 | AstraZeneca AB | CDE ↗ |
| JYHB2101440 | Supplement | 2021/09/23 | AstraZeneca AB | CDE ↗ |
| JYHB2101439 | Supplement | 2021/09/23 | AstraZeneca AB | CDE ↗ |
| JYHZ2100602 | Import re-registration | 2021/08/11 | AstraZeneca AB; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2100601 | Import re-registration | 2021/08/11 | AstraZeneca AB; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
No verified English name 16 records · Latest accepted 2026/08/11
Import · 11Supplement · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2600334 | Import | 2026/08/11 | AstraZeneca AB; AstraZeneca Investment (China) Co. Limited | CDE ↗ |
| JXHL2600268 | Import | 2026/07/10 | AstraZeneca AB; AstraZeneca Investment (China) Co. Limited | CDE ↗ |
| JXHL2500107 | Import | 2025/05/12 | AstraZeneca AB; AstraZeneca Investment (China) Co. Limited | CDE ↗ |
| JXHB2400118 | Supplement | 2024/07/02 | AstraZeneca AB; Patheon Manufacturing Services LLC | CDE ↗ |
| JXHB2400117 | Supplement | 2024/07/02 | AstraZeneca AB; Patheon Manufacturing Services LLC | CDE ↗ |
| JXHL2400137 | Import | 2024/06/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Limited | CDE ↗ |
| JXHB2400047 | Supplement | 2024/02/27 | AstraZeneca AB; Patheon Manufacturing Services LLC | CDE ↗ |
| JXHB2400046 | Supplement | 2024/02/27 | AstraZeneca AB; Patheon Manufacturing Services LLC | CDE ↗ |
| JXHL2400037 | Import | 2024/02/22 | AstraZeneca AB; AstraZeneca Investment (China) Co. Limited | CDE ↗ |
| JXHL2300286 | Import | 2023/11/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Limited | CDE ↗ |
| JXHB2300157 | Supplement | 2023/10/10 | AstraZeneca AB; Patheon Manufacturing Services LLC | CDE ↗ |
| JXHL2300170 | Import | 2023/07/18 | AstraZeneca AB; AstraZeneca Investment (China) Co. Limited | CDE ↗ |
| JXHL2300166 | Import | 2023/07/17 | AstraZeneca AB; AstraZeneca Investment (China) Co. Limited | CDE ↗ |
| JXHL2300035 | Import | 2023/02/27 | AstraZeneca AB; AstraZeneca Investment (China) Co. Limited | CDE ↗ |
| JXHL2100051 | Import | 2021/02/11 | AstraZeneca AB | CDE ↗ |
| JXHL2100050 | Import | 2021/02/11 | AstraZeneca AB | CDE ↗ |
No verified English name 9 records · Latest accepted 2026/07/30
Import · 5Supplement · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2600179 | Import | 2026/07/30 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2600172 | Import | 2026/07/20 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2600061 | Supplement | 2026/04/29 | AstraZeneca AB; BSP Pharmaceuticals S.p.A. | CDE ↗ |
| JXSB2500143 | Supplement | 2025/11/28 | AstraZeneca AB; BSP Pharmaceuticals S.p.A. | CDE ↗ |
| JXSL2500188 | Import | 2025/09/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2500121 | Import | 2025/07/12 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2400127 | Supplement | 2024/10/10 | AstraZeneca AB; BSP Pharmaceuticals S.p.A. | CDE ↗ |
| JXSB2400020 | Supplement | 2024/03/02 | AstraZeneca AB; BSP Pharmaceuticals S.p.A. | CDE ↗ |
| JXSL2300158 | Import | 2023/08/25 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 4 records · Latest accepted 2026/07/30
Not stated by source · 1Import re-registration · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JTH2600160 | Not stated by source | 2026/07/30 | AstraZeneca AB; AstraZeneca GmbH; Shanghai Xin Huang He Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| JYHZ2500095 | Import re-registration | 2025/04/23 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHZ2300381 | Import re-registration | 2023/09/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHZ2300380 | Import re-registration | 2023/09/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
No verified English name 35 records · Latest accepted 2026/07/29
Supplement · 20Import · 15
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSB2600132 | Supplement | 2026/07/29 | AstraZeneca AB; AstraZeneca Nijmegen B.V.; Samsung Biologics Co. Ltd. | CDE ↗ |
| JXSB2500164 | Supplement | 2025/12/26 | AstraZeneca AB; AstraZeneca Nijmegen B.V.; Samsung Biologics Co. Ltd. | CDE ↗ |
| JXSB2500148 | Supplement | 2025/12/13 | AstraZeneca AB; AstraZeneca Nijmegen B.V.; Samsung Biologics Co. Ltd. | CDE ↗ |
| JXSB2500122 | Supplement | 2025/09/12 | AstraZeneca AB; AstraZeneca Nijmegen B.V.; Samsung Biologics Co. Ltd. | CDE ↗ |
| JXSB2500099 | Supplement | 2025/08/27 | AstraZeneca AB; AstraZeneca Nijmegen B.V.; Samsung Biologics Co. Ltd. | CDE ↗ |
| JXSB2500093 | Supplement | 2025/08/21 | AstraZeneca AB; AstraZeneca Nijmegen B.V.; Samsung Biologics Co. Ltd. | CDE ↗ |
| JXSB2500092 | Supplement | 2025/08/21 | AstraZeneca AB; AstraZeneca Nijmegen B.V.; Samsung Biologics Co. Ltd. | CDE ↗ |
| JXSL2500148 | Import | 2025/08/14 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2500032 | Supplement | 2025/04/22 | AstraZeneca AB; AstraZeneca Nijmegen B.V.; Samsung Biologics Co. Ltd. | CDE ↗ |
| JXSL2500056 | Import | 2025/04/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2500030 | Supplement | 2025/04/08 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2500002 | Supplement | 2025/01/18 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2400254 | Import | 2024/12/27 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2400158 | Supplement | 2024/11/28 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2400187 | Import | 2024/09/30 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400186 | Import | 2024/09/29 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400185 | Import | 2024/09/27 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400178 | Import | 2024/09/25 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2400115 | Supplement | 2024/08/14 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2400113 | Supplement | 2024/08/09 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2400086 | Supplement | 2024/07/03 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2400085 | Supplement | 2024/07/03 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2400084 | Supplement | 2024/07/03 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2400039 | Supplement | 2024/04/18 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2400055 | Import | 2024/03/05 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400048 | Import | 2024/02/21 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2300164 | Supplement | 2023/12/14 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2300121 | Supplement | 2023/10/09 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2300131 | Import | 2023/07/20 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2300116 | Import | 2023/06/29 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2300081 | Supplement | 2023/06/29 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2300110 | Import | 2023/06/16 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2300075 | Import | 2023/04/22 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2200206 | Import | 2022/12/23 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2200191 | Import | 2022/11/05 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/07/28
Import · 2
No verified English name 4 records · Latest accepted 2026/07/14
Supplement · 3Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600385 | Supplement | 2026/07/14 | AstraZeneca AB; Bespak HC Limited | CDE ↗ |
| JYHZ2400247 | Import re-registration | 2024/09/19 | AstraZeneca AB; Bespak HC Limited; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHB2101218 | Supplement | 2021/06/29 | AstraZeneca AB; Recipharm HC Limited | CDE ↗ |
| JYHB2101070 | Supplement | 2021/04/28 | AstraZeneca AB; Recipharm HC Limited | CDE ↗ |
No verified English name 15 records · Latest accepted 2026/07/03
Import · 14Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2600252 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600251 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600250 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600249 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600248 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600247 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600246 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600245 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600244 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600243 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600242 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600241 | Import | 2026/07/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2500079 | Import | 2025/04/15 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHB2500001 | Supplement | 2025/01/23 | AstraZeneca AB; Patheon Italia S.p.A. | CDE ↗ |
| JXHL2400243 | Import | 2024/10/11 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2026/06/26
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSS2600055 | Import | 2026/06/26 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/06/25
Import · 2
No verified English name 1 records · Latest accepted 2026/06/23
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2600148 | Import | 2026/06/23 | AstraZeneca AB; AstraZeneca Global R&D(China)Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2026/06/23
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2600149 | Import | 2026/06/23 | AstraZeneca AB; AstraZeneca Global R&D(China)Co. Ltd. | CDE ↗ |
No verified English name 9 records · Latest accepted 2026/06/12
Supplement · 6Import · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSB2600093 | Supplement | 2026/06/12 | AstraZeneca AB; BSP Pharmaceuticals S.p.A. | CDE ↗ |
| JXSB2500073 | Supplement | 2025/07/28 | AstraZeneca AB; BSP Pharmaceuticals S.p.A. | CDE ↗ |
| JXSB2500001 | Supplement | 2025/01/15 | AstraZeneca AB; BSP Pharmaceuticals S.p.A. | CDE ↗ |
| JXSL2400134 | Import | 2024/07/30 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400133 | Import | 2024/07/30 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2400068 | Supplement | 2024/06/05 | AstraZeneca AB; BSP Pharmaceuticals S.p.A. | CDE ↗ |
| JXSB2300130 | Supplement | 2023/11/14 | AstraZeneca AB; BSP Pharmaceuticals S.p.A. | CDE ↗ |
| JXSB2300109 | Supplement | 2023/09/02 | AstraZeneca AB; BSP Pharmaceuticals S.p.A. | CDE ↗ |
| JXSL2300048 | Import | 2023/03/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 4 records · Latest accepted 2026/06/08
Import re-registration · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600137 | Import re-registration | 2026/06/08 | AstraZeneca AB; Kagamiishi Plant Nipro Pharma Corporation; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYHZ2600136 | Import re-registration | 2026/06/08 | AstraZeneca AB; Kagamiishi Plant Nipro Pharma Corporation; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYHZ2100748 | Import re-registration | 2021/12/30 | AstraZeneca AB; Kagamiishi Plant Nipro Pharma Corporation; AstraZeneca Investment(China) Co. Ltd | CDE ↗ |
| JYHZ2100747 | Import re-registration | 2021/12/30 | AstraZeneca AB; Kagamiishi Plant Nipro Pharma Corporation; AstraZeneca Investment(China) Co. Ltd | CDE ↗ |
No verified English name 1 records · Latest accepted 2026/05/26
Not stated by source · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JTS2600096 | Not stated by source | 2026/05/26 | AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
No verified English name 9 records · Latest accepted 2026/05/26
Import · 7Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2600189 | Import | 2026/05/26 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHB2600010 | Supplement | 2026/01/28 | AstraZeneca AB | CDE ↗ |
| JXHB2600009 | Supplement | 2026/01/28 | AstraZeneca AB | CDE ↗ |
| JXHL2400070 | Import | 2024/03/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2400069 | Import | 2024/03/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2400064 | Import | 2024/03/15 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2400063 | Import | 2024/03/15 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2300004 | Import | 2023/01/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2300003 | Import | 2023/01/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/05/09
Import · 2
No verified English name 32 records · Latest accepted 2026/05/08
Import · 32
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2600157 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600156 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600155 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600154 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600153 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600152 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600151 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600150 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600148 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600147 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600146 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600145 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600144 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600143 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600142 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600141 | Import | 2026/05/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600134 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600133 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600132 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600131 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600130 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600129 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600128 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600127 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600126 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600125 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600124 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600123 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600122 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600121 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600120 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2600119 | Import | 2026/04/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 18 records · Latest accepted 2026/04/03
Import · 13Not stated by source · 2Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2600099 | Import | 2026/04/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHS2600026 | Import | 2026/02/13 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHS2600025 | Import | 2026/02/13 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JTH2500166 | Not stated by source | 2025/11/05 | AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| JTH2500165 | Not stated by source | 2025/11/05 | AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| JXHB2500138 | Supplement | 2025/10/18 | AstraZeneca AB; Patheon Pharmaceuticals Inc. | CDE ↗ |
| JXHL2500138 | Import | 2025/06/12 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2500137 | Import | 2025/06/12 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHB2500041 | Supplement | 2025/04/09 | AstraZeneca AB; Patheon Pharmaceuticals Inc. | CDE ↗ |
| JXHB2500040 | Supplement | 2025/04/09 | AstraZeneca AB; Patheon Pharmaceuticals Inc. | CDE ↗ |
| JXHL2400291 | Import | 2024/12/12 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2400290 | Import | 2024/12/12 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2400264 | Import | 2024/11/06 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2400263 | Import | 2024/11/06 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2400008 | Import | 2024/01/10 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2400007 | Import | 2024/01/10 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2300285 | Import | 2023/11/15 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2300283 | Import | 2023/11/15 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/04/02
Import · 2
No verified English name 2 records · Latest accepted 2026/04/01
Supplement · 1Import · 1
Olaparib Tablets 30 records · Latest accepted 2026/03/24
Supplement · 16Import · 12Import re-registration · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600193 | Supplement | 2026/03/24 | AstraZeneca AB; AbbVie Limited | CDE ↗ |
| JYHB2600192 | Supplement | 2026/03/24 | AstraZeneca AB; AbbVie Limited | CDE ↗ |
| JYHB2500280 | Supplement | 2025/05/22 | AstraZeneca AB; AbbVie Limited | CDE ↗ |
| JYHB2500279 | Supplement | 2025/05/22 | AstraZeneca AB; AbbVie Limited | CDE ↗ |
| JXHL2500083 | Import | 2025/04/16 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2500082 | Import | 2025/04/16 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHB2400174 | Supplement | 2024/11/08 | AstraZeneca AB | CDE ↗ |
| JXHB2400173 | Supplement | 2024/11/08 | AstraZeneca AB | CDE ↗ |
| JXHS2400081 | Import | 2024/10/11 | AstraZeneca AB; AbbVie Limited; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHS2400080 | Import | 2024/10/11 | AstraZeneca AB; AbbVie Limited; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHS2400004 | Import | 2024/01/09 | AstraZeneca AB; AbbVie Limited; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHS2400003 | Import | 2024/01/09 | AstraZeneca AB; AbbVie Limited; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHB2300513 | Supplement | 2023/09/07 | AstraZeneca AB; AbbVie Limited | CDE ↗ |
| JYHB2300512 | Supplement | 2023/09/07 | AstraZeneca AB; AbbVie Limited | CDE ↗ |
| JXHB2300096 | Supplement | 2023/06/10 | AstraZeneca AB | CDE ↗ |
| JXHB2300095 | Supplement | 2023/06/10 | AstraZeneca AB | CDE ↗ |
| JYHZ2200256 | Import re-registration | 2022/09/22 | AstraZeneca AB; AbbVie Limited; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHZ2200255 | Import re-registration | 2022/09/22 | AstraZeneca AB; AbbVie Limited; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHB2200123 | Supplement | 2022/09/02 | AstraZeneca AB | CDE ↗ |
| JXHB2200122 | Supplement | 2022/09/02 | AstraZeneca AB | CDE ↗ |
| JYHB2200066 | Supplement | 2022/01/30 | AstraZeneca AB; AbbVie Limited | CDE ↗ |
| JYHB2200065 | Supplement | 2022/01/30 | AstraZeneca AB; AbbVie Limited | CDE ↗ |
| JXHS2101104 | Import | 2021/12/31 | AstraZeneca AB; AbbVie Limited; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHS2101103 | Import | 2021/12/31 | AstraZeneca AB; AbbVie Limited; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2100039 | Import | 2021/02/03 | AstraZeneca AB | CDE ↗ |
| JXHL2100038 | Import | 2021/02/03 | AstraZeneca AB | CDE ↗ |
| JXHS2100001 | Import | 2021/01/12 | AstraZeneca AB; AbbVie Limited | CDE ↗ |
| JXHS2100002 | Import | 2021/01/08 | AstraZeneca AB; AbbVie Limited | CDE ↗ |
| JXHB2100002 | Supplement | 2021/01/06 | AstraZeneca AB | CDE ↗ |
| JXHB2100001 | Supplement | 2021/01/06 | AstraZeneca AB | CDE ↗ |
No verified English name 4 records · Latest accepted 2026/02/13
Not stated by source · 2Import · 1Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JTS2600027 | Not stated by source | 2026/02/13 | AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| JTS2600026 | Not stated by source | 2026/02/13 | AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| JXSL2500009 | Import | 2025/01/16 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2400047 | Supplement | 2024/05/08 | AstraZeneca AB; Patheon Manufacturing Services LLC | CDE ↗ |
No verified English name 1 records · Latest accepted 2026/02/07
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2600033 | Import | 2026/02/07 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 28 records · Latest accepted 2026/02/05
Supplement · 18Import re-registration · 2Import · 8
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600082 | Supplement | 2026/02/05 | AstraZeneca AB; AndersonBrecon Inc.; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2600081 | Supplement | 2026/02/05 | AstraZeneca AB; AndersonBrecon Inc.; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2500697 | Supplement | 2025/12/22 | AstraZeneca AB; AndersonBrecon Inc. | CDE ↗ |
| JYHB2500696 | Supplement | 2025/12/22 | AstraZeneca AB; AndersonBrecon Inc. | CDE ↗ |
| JYHB2500282 | Supplement | 2025/05/23 | AstraZeneca AB; AndersonBrecon Inc. | CDE ↗ |
| JYHB2500281 | Supplement | 2025/05/23 | AstraZeneca AB; AndersonBrecon Inc. | CDE ↗ |
| JYHB2500153 | Supplement | 2025/03/14 | AstraZeneca AB; AndersonBrecon Inc. | CDE ↗ |
| JYHB2500152 | Supplement | 2025/03/14 | AstraZeneca AB; AndersonBrecon Inc. | CDE ↗ |
| JYHZ2400018 | Import re-registration | 2024/01/24 | AstraZeneca AB; AndersonBrecon Inc.; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHZ2400017 | Import re-registration | 2024/01/24 | AstraZeneca AB; AndersonBrecon Inc.; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHB2300300 | Supplement | 2023/05/23 | AstraZeneca AB; AndersonBrecon Inc. | CDE ↗ |
| JYHB2300299 | Supplement | 2023/05/23 | AstraZeneca AB; AndersonBrecon Inc. | CDE ↗ |
| JYHB2300097 | Supplement | 2023/02/08 | AstraZeneca AB; AndersonBrecon Inc. | CDE ↗ |
| JYHB2300096 | Supplement | 2023/02/08 | AstraZeneca AB; AndersonBrecon Inc. | CDE ↗ |
| JYHB2200488 | Supplement | 2022/09/05 | AstraZeneca AB; AndersonBrecon Inc. | CDE ↗ |
| JYHB2200487 | Supplement | 2022/09/05 | AstraZeneca AB; AndersonBrecon Inc. | CDE ↗ |
| JXHB2200022 | Supplement | 2022/02/21 | AstraZeneca AB; Sharp Corporation | CDE ↗ |
| JXHB2200021 | Supplement | 2022/02/21 | AstraZeneca AB; Sharp Corporation | CDE ↗ |
| JXHB2200020 | Supplement | 2022/02/21 | AstraZeneca AB; Fisher Clinical Services GmbH | CDE ↗ |
| JXHB2200019 | Supplement | 2022/02/21 | AstraZeneca AB; Fisher Clinical Services GmbH | CDE ↗ |
| JXHL2101157 | Import | 2021/08/09 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2101156 | Import | 2021/08/09 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2101125 | Import | 2021/07/08 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2101124 | Import | 2021/07/08 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2101123 | Import | 2021/07/08 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2101122 | Import | 2021/07/08 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2100042 | Import | 2021/02/03 | AstraZeneca AB | CDE ↗ |
| JXHL2100041 | Import | 2021/02/03 | AstraZeneca AB | CDE ↗ |
No verified English name 11 records · Latest accepted 2025/12/30
Supplement · 6Import · 4Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500727 | Supplement | 2025/12/30 | AstraZeneca AB; ASTRAZENECA DUNKERQUE PRODUCTION | CDE ↗ |
| JXHS2500105 | Import | 2025/09/17 | AstraZeneca AB; ASTRAZENECA DUNKERQUE PRODUCTION; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHS2500104 | Import | 2025/09/17 | AstraZeneca AB; ASTRAZENECA DUNKERQUE PRODUCTION; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHB2400685 | Supplement | 2024/12/27 | AstraZeneca AB; ASTRAZENECA DUNKERQUE PRODUCTION; Bespak HC Limited | CDE ↗ |
| JYHZ2400110 | Import re-registration | 2024/05/09 | AstraZeneca AB; ASTRAZENECA DUNKERQUE PRODUCTION; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXHL2400013 | Import | 2024/01/19 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2300324 | Import | 2023/12/23 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYHB2200287 | Supplement | 2022/06/09 | AstraZeneca AB; ASTRAZENECA DUNKERQUE PRODUCTION | CDE ↗ |
| JYHB2200286 | Supplement | 2022/06/09 | AstraZeneca AB; ASTRAZENECA DUNKERQUE PRODUCTION | CDE ↗ |
| JYHB2200076 | Supplement | 2022/02/11 | AstraZeneca AB; ASTRAZENECA DUNKERQUE PRODUCTION | CDE ↗ |
| JYHB2200075 | Supplement | 2022/02/11 | AstraZeneca AB; ASTRAZENECA DUNKERQUE PRODUCTION | CDE ↗ |
Saxagliptin and Metformin Hydrochloride Sustained-release Tablets 6 records · Latest accepted 2025/12/25
Import re-registration · 4Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2500307 | Import re-registration | 2025/12/25 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2500305 | Import re-registration | 2025/12/25 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHB2300376 | Supplement | 2023/07/08 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2300373 | Supplement | 2023/07/08 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHZ2100557 | Import re-registration | 2021/06/09 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2100554 | Import re-registration | 2021/06/09 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
No verified English name 6 records · Latest accepted 2025/12/25
Import re-registration · 4Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2500306 | Import re-registration | 2025/12/25 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2500304 | Import re-registration | 2025/12/25 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHB2300377 | Supplement | 2023/07/08 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2300374 | Supplement | 2023/07/08 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHZ2100558 | Import re-registration | 2021/06/09 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2100555 | Import re-registration | 2021/06/09 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
Saxagliptin and Metformin Hydrochloride Sustained-release Tablets 6 records · Latest accepted 2025/12/25
Import re-registration · 4Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2500308 | Import re-registration | 2025/12/25 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2500303 | Import re-registration | 2025/12/25 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHB2300378 | Supplement | 2023/07/08 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2300375 | Supplement | 2023/07/08 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHZ2100559 | Import re-registration | 2021/06/09 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2100556 | Import re-registration | 2021/06/09 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
Dapagliflozin Tablets 22 records · Latest accepted 2025/12/10
Import re-registration · 8Import · 4Supplement · 10
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2500284 | Import re-registration | 2025/12/10 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2500283 | Import re-registration | 2025/12/10 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2500282 | Import re-registration | 2025/12/10 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2500281 | Import re-registration | 2025/12/10 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JXHS2200080 | Import | 2022/09/10 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JXHS2200079 | Import | 2022/09/10 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHB2101317 | Supplement | 2021/08/12 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2101316 | Supplement | 2021/08/12 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2101315 | Supplement | 2021/08/12 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2101314 | Supplement | 2021/08/12 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2101225 | Supplement | 2021/07/01 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2101224 | Supplement | 2021/07/01 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHZ2100522 | Import re-registration | 2021/04/19 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2100521 | Import re-registration | 2021/04/19 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2100520 | Import re-registration | 2021/04/19 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JYHZ2100519 | Import re-registration | 2021/04/19 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
| JXHS2100010 | Import | 2021/01/23 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JXHS2100009 | Import | 2021/01/23 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JXHB2100011 | Supplement | 2021/01/22 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JXHB2100010 | Supplement | 2021/01/22 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2100083 | Supplement | 2021/01/21 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2100082 | Supplement | 2021/01/21 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/11/28
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2500231 | Import | 2025/11/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) 4 records · Latest accepted 2025/11/12
Supplement · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500611 | Supplement | 2025/11/12 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2500610 | Supplement | 2025/11/12 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2500033 | Supplement | 2025/01/24 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHB2500032 | Supplement | 2025/01/24 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/11/12
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500612 | Supplement | 2025/11/12 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/11/12
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500613 | Supplement | 2025/11/12 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/11/12
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500614 | Supplement | 2025/11/12 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/10/14
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500517 | Supplement | 2025/10/14 | AstraZeneca AB | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/09/28
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2500187 | Import | 2025/09/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 3 records · Latest accepted 2025/09/13
Supplement · 1Import · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHB2500130 | Supplement | 2025/09/13 | AstraZeneca AB; AstraZeneca AB R&D Gothenburg | CDE ↗ |
| JXHL2500106 | Import | 2025/05/10 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2400151 | Import | 2024/07/02 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/09/09
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2500172 | Import | 2025/09/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/09/09
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2500171 | Import | 2025/09/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 10 records · Latest accepted 2025/09/02
Import · 7Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSS2500117 | Import | 2025/09/02 | AstraZeneca AB; Name not romanized | CDE ↗ |
| JXSS2500116 | Import | 2025/09/02 | AstraZeneca AB; Name not romanized | CDE ↗ |
| JYSB2500105 | Supplement | 2025/04/16 | AstraZeneca AB; Catalent Indiana LLC | CDE ↗ |
| JYSB2500101 | Supplement | 2025/04/10 | AstraZeneca AB | CDE ↗ |
| JYSB2500100 | Supplement | 2025/04/10 | AstraZeneca AB | CDE ↗ |
| JXSS2500040 | Import | 2025/04/03 | AstraZeneca AB; Name not romanized | CDE ↗ |
| JXSS2500039 | Import | 2025/04/03 | AstraZeneca AB; Name not romanized | CDE ↗ |
| JXSL2500019 | Import | 2025/01/25 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXSS2400041 | Import | 2024/05/14 | AstraZeneca AB; Name not romanized | CDE ↗ |
| JXSS2300050 | Import | 2023/06/29 | AstraZeneca AB; Name not romanized | CDE ↗ |
No verified English name 6 records · Latest accepted 2025/06/28
Supplement · 5Not stated by source · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHB2500080 | Supplement | 2025/06/28 | AstraZeneca AB | CDE ↗ |
| JXHB2400194 | Supplement | 2024/11/26 | AstraZeneca AB | CDE ↗ |
| JXHB2300176 | Supplement | 2023/12/01 | AstraZeneca AB | CDE ↗ |
| JXHB2200101 | Supplement | 2022/07/19 | AstraZeneca AB | CDE ↗ |
| JTH2100549 | Not stated by source | 2021/06/15 | AstraZeneca AB; AstraZeneca Pty Ltd; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| JYHB2101116 | Supplement | 2021/05/21 | AstraZeneca AB | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/06/17
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2500090 | Import | 2025/06/17 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd | CDE ↗ |
No verified English name 3 records · Latest accepted 2025/06/14
Import · 3
No verified English name 1 records · Latest accepted 2025/05/20
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2500076 | Import | 2025/05/20 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/05/14
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2500075 | Import | 2025/05/14 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 16 records · Latest accepted 2025/05/13
Import · 8Supplement · 6Not stated by source · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2500109 | Import | 2025/05/13 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2500108 | Import | 2025/05/13 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHB2500061 | Supplement | 2025/05/07 | AstraZeneca AB | CDE ↗ |
| JXHB2500060 | Supplement | 2025/05/07 | AstraZeneca AB | CDE ↗ |
| JXHL2400139 | Import | 2024/06/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2400138 | Import | 2024/06/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2400101 | Import | 2024/05/09 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2400100 | Import | 2024/05/09 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2400087 | Import | 2024/04/08 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2400086 | Import | 2024/04/08 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHB2400012 | Supplement | 2024/01/06 | AstraZeneca AB | CDE ↗ |
| JXHB2400011 | Supplement | 2024/01/06 | AstraZeneca AB | CDE ↗ |
| JTH2300136 | Not stated by source | 2023/05/31 | AstraZeneca AB; AstraZeneca UK Limited; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| JTH2300135 | Not stated by source | 2023/05/31 | AstraZeneca AB; AstraZeneca UK Limited; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| JXHB2200118 | Supplement | 2022/08/26 | AstraZeneca AB | CDE ↗ |
| JXHB2200117 | Supplement | 2022/08/26 | AstraZeneca AB | CDE ↗ |
No verified English name 2 records · Latest accepted 2025/04/15
Import · 2
No verified English name 4 records · Latest accepted 2025/02/21
Import · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSS2500016 | Import | 2025/02/21 | AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSS2500015 | Import | 2025/02/21 | AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSS2400099 | Import | 2024/10/18 | AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSS2400097 | Import | 2024/10/18 | AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 3 records · Latest accepted 2025/02/11
Supplement · 2Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSB2500009 | Supplement | 2025/02/11 | AstraZeneca AB; Baxter Oncology GmbH | CDE ↗ |
| JXSB2400122 | Supplement | 2024/08/28 | AstraZeneca AB; Baxter Oncology GmbH | CDE ↗ |
| JXSL2300234 | Import | 2023/12/25 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd | CDE ↗ |
No verified English name 4 records · Latest accepted 2025/02/08
Import · 3Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2500021 | Import | 2025/02/08 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXSL2300127 | Import | 2023/07/11 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXSL2200135 | Import | 2022/08/18 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXSB2100001 | Supplement | 2021/01/06 | AstraZeneca AB; Amgen Inc. | CDE ↗ |
No verified English name 6 records · Latest accepted 2024/12/20
Import · 6
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2400245 | Import | 2024/12/20 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400244 | Import | 2024/12/20 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400243 | Import | 2024/12/20 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400160 | Import | 2024/09/04 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400159 | Import | 2024/09/04 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2400158 | Import | 2024/09/04 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2024/12/18
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2400241 | Import | 2024/12/18 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
Saxagliptin Tablets 6 records · Latest accepted 2024/11/26
Import re-registration · 4Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2400315 | Import re-registration | 2024/11/26 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHZ2400314 | Import re-registration | 2024/11/26 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHZ2400313 | Import re-registration | 2024/11/26 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHZ2400312 | Import re-registration | 2024/11/26 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHF2100004 | Supplement | 2021/01/16 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| JYHF2100003 | Supplement | 2021/01/16 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP | CDE ↗ |
No verified English name 2 records · Latest accepted 2024/11/13
Supplement · 1Import · 1
No verified English name 10 records · Latest accepted 2024/10/23
Supplement · 4Import · 6
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSB2400136 | Supplement | 2024/10/23 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2400135 | Supplement | 2024/10/23 | AstraZeneca AB; Vetter Development Services USA Inc. | CDE ↗ |
| JXSB2400061 | Supplement | 2024/05/28 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2400078 | Import | 2024/04/20 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXSB2400013 | Supplement | 2024/02/05 | AstraZeneca AB; Vetter Development Services USA Inc. | CDE ↗ |
| JXSL2300160 | Import | 2023/09/01 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXSL2300135 | Import | 2023/07/22 | AstraZeneca AB; AstraZeneca Investment (China)Co. Ltd | CDE ↗ |
| JXSL2300115 | Import | 2023/06/27 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXSL2300092 | Import | 2023/05/12 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXSL2101106 | Import | 2021/09/02 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
No verified English name 5 records · Latest accepted 2024/09/29
Import · 3Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHS2400075 | Import | 2024/09/29 | AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHB2400024 | Supplement | 2024/01/19 | AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG. | CDE ↗ |
| JXHB2400023 | Supplement | 2024/01/19 | AstraZeneca AB; Vetter Development Services USA Inc. | CDE ↗ |
| JXHL2300301 | Import | 2023/12/05 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2300111 | Import | 2023/05/10 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 2 records · Latest accepted 2024/09/14
Import · 2
No verified English name 8 records · Latest accepted 2024/07/09
Supplement · 4Import · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSB2400092 | Supplement | 2024/07/09 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2400012 | Import | 2024/01/10 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2300124 | Supplement | 2023/10/11 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2300112 | Supplement | 2023/09/15 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSB2300073 | Supplement | 2023/06/08 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2300027 | Import | 2023/01/31 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2200155 | Import | 2022/09/06 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2200059 | Import | 2022/05/24 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2024/06/04
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2400110 | Import | 2024/06/04 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 10 records · Latest accepted 2024/01/24
Supplement · 8Import · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHB2400026 | Supplement | 2024/01/24 | AstraZeneca AB; Patheon Pharmaceuticals Inc. | CDE ↗ |
| JXHB2400025 | Supplement | 2024/01/24 | AstraZeneca AB; Patheon Pharmaceuticals Inc. | CDE ↗ |
| JXHB2200051 | Supplement | 2022/04/20 | AstraZeneca AB; Patheon Pharmaceuticals Inc. | CDE ↗ |
| JXHB2200050 | Supplement | 2022/04/20 | AstraZeneca AB; Patheon Pharmaceuticals Inc. | CDE ↗ |
| JXHB2101083 | Supplement | 2021/10/28 | AstraZeneca AB; Patheon Pharmaceuticals Inc. | CDE ↗ |
| JXHB2101082 | Supplement | 2021/10/28 | AstraZeneca AB; Patheon Pharmaceuticals Inc. | CDE ↗ |
| JXHL2101049 | Import | 2021/05/20 | AstraZeneca AB; AstraZeneca Investment (China) Co. Limited | CDE ↗ |
| JXHL2101048 | Import | 2021/05/20 | AstraZeneca AB; AstraZeneca Investment (China) Co. Limited | CDE ↗ |
| JXHB2101013 | Supplement | 2021/05/12 | AstraZeneca AB; Patheon Pharmaceuticals Incorporated | CDE ↗ |
| JXHB2101012 | Supplement | 2021/05/12 | AstraZeneca AB; Patheon Pharmaceuticals Incorporated | CDE ↗ |
Fulvestrant Injection 4 records · Latest accepted 2024/01/17
Supplement · 3Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2400019 | Supplement | 2024/01/17 | AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG | CDE ↗ |
| JYHZ2300293 | Import re-registration | 2023/07/13 | AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG; AstraZeneca Investment(China) Co. Ltd. | CDE ↗ |
| JXHB2200057 | Supplement | 2022/04/28 | AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG | CDE ↗ |
| JYHB2101101 | Supplement | 2021/05/21 | AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG | CDE ↗ |
No verified English name 1 records · Latest accepted 2024/01/11
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2400011 | Import | 2024/01/11 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
No verified English name 9 records · Latest accepted 2023/12/26
Import · 5Not stated by source · 2Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2300235 | Import | 2023/12/26 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JXSL2300188 | Import | 2023/10/21 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JTS2300015 | Not stated by source | 2023/03/17 | AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| JTS2300014 | Not stated by source | 2023/03/17 | AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| JXSB2101031 | Supplement | 2021/07/08 | AstraZeneca AB; Catalent Indiana LLC | CDE ↗ |
| JXSL2101022 | Import | 2021/05/08 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXSL2101008 | Import | 2021/04/14 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYSB2100093 | Supplement | 2021/04/08 | AstraZeneca AB; Catalent Indiana LLC | CDE ↗ |
| JXSL2100018 | Import | 2021/02/05 | AstraZeneca AB | CDE ↗ |
No verified English name 2 records · Latest accepted 2023/12/20
Import · 2
No verified English name 1 records · Latest accepted 2023/12/16
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSS2300093 | Import | 2023/12/16 | AstraZeneca AB; Baxter Pharmaceutical Solutions LLC; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2023/12/13
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSB2300161 | Supplement | 2023/12/13 | AstraZeneca AB; AstraZeneca Nijmegen BV | CDE ↗ |
No verified English name 1 records · Latest accepted 2023/09/15
Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2300379 | Import re-registration | 2023/09/15 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
No verified English name 5 records · Latest accepted 2023/08/15
Import · 4Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2300150 | Import | 2023/08/15 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2300023 | Import | 2023/01/13 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSL2300004 | Import | 2023/01/04 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXSB2200016 | Supplement | 2022/01/30 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| JXSL2101121 | Import | 2021/10/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
Metoprolol Succinate Sustained-release Tablets 6 records · Latest accepted 2023/07/14
Import re-registration · 6
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2300302 | Import re-registration | 2023/07/14 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYHZ2300301 | Import re-registration | 2023/07/14 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYHZ2300300 | Import re-registration | 2023/07/14 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYHZ2300299 | Import re-registration | 2023/07/14 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYHZ2300298 | Import re-registration | 2023/07/14 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JYHZ2300297 | Import re-registration | 2023/07/14 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
No verified English name 2 records · Latest accepted 2023/05/12
Import · 2
No verified English name 2 records · Latest accepted 2023/04/24
Supplement · 1Import re-registration · 1
No verified English name 1 records · Latest accepted 2023/04/11
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2300076 | Import | 2023/04/11 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2023/03/24
Not stated by source · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JTH2300086 | Not stated by source | 2023/03/24 | AstraZeneca AB; AstraZeneca Pty Ltd; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2023/03/02
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2300044 | Import | 2023/03/02 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
Exenatide Injection 4 records · Latest accepted 2023/01/19
Import re-registration · 2Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2300037 | Import re-registration | 2023/01/19 | AstraZeneca AB; Baxter Pharmaceutical Solutions LLC; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHZ2300036 | Import re-registration | 2023/01/19 | AstraZeneca AB; Baxter Pharmaceutical Solutions LLC; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| JYHB2200688 | Supplement | 2022/12/31 | AstraZeneca AB; Baxter Pharmaceutical Solutions LLC | CDE ↗ |
| JYHB2200687 | Supplement | 2022/12/31 | AstraZeneca AB; Baxter Pharmaceutical Solutions LLC | CDE ↗ |
No verified English name 2 records · Latest accepted 2022/11/01
Import · 2
No verified English name 2 records · Latest accepted 2022/08/12
Import re-registration · 2
No verified English name 1 records · Latest accepted 2022/07/19
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2200204 | Import | 2022/07/19 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd | CDE ↗ |
No verified English name 5 records · Latest accepted 2022/07/18
Supplement · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHB2200100 | Supplement | 2022/07/18 | AstraZeneca AB | CDE ↗ |
| JXHB2200099 | Supplement | 2022/07/18 | AstraZeneca AB | CDE ↗ |
| JXHB2101114 | Supplement | 2021/12/14 | AstraZeneca AB | CDE ↗ |
| JXHB2101113 | Supplement | 2021/12/14 | AstraZeneca AB | CDE ↗ |
| JXHB2101112 | Supplement | 2021/12/14 | AstraZeneca AB | CDE ↗ |
No verified English name 8 records · Latest accepted 2022/06/03
Import · 4Supplement · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2200128 | Import | 2022/06/03 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2200127 | Import | 2022/06/03 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHB2101107 | Supplement | 2021/11/26 | AstraZeneca AB | CDE ↗ |
| JXHB2101106 | Supplement | 2021/11/26 | AstraZeneca AB | CDE ↗ |
| JXHB2101035 | Supplement | 2021/07/03 | AstraZeneca AB | CDE ↗ |
| JXHB2101034 | Supplement | 2021/07/02 | AstraZeneca AB | CDE ↗ |
| JXHL2101051 | Import | 2021/05/20 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| JXHL2101050 | Import | 2021/05/20 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
No verified English name 3 records · Latest accepted 2022/05/11
Import · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2200108 | Import | 2022/05/11 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2200107 | Import | 2022/05/11 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHL2101037 | Import | 2021/05/14 | AstraZeneca AB; AstraZeneca Investment (China)Co. Ltd. | CDE ↗ |
Dapagliflozin And Metformin Hydrochloride Extended-Release Tablets 5 records · Latest accepted 2022/02/08
Import · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHS2200023 | Import | 2022/02/08 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHS2200022 | Import | 2022/02/08 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHS2200021 | Import | 2022/02/08 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHS2200020 | Import | 2022/02/08 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| JXHS2200019 | Import | 2022/02/08 | AstraZeneca AB; AstraZeneca Pharmaceuticals LP; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2022/01/07
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2200004 | Import | 2022/01/07 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2022/01/07
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSL2200003 | Import | 2022/01/07 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2021/12/16
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2101272 | Import | 2021/12/16 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2021/09/03
Not stated by source · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JTH2100638 | Not stated by source | 2021/09/03 | AstraZeneca AB; AstraZeneca UK Limited; He Ji Huang Pu Pharmaceuticals (Shanghai) Co., Ltd. romanized | CDE ↗ |
Exenatide Microspheres For Injection 1 records · Latest accepted 2021/05/10
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2101083 | Supplement | 2021/05/10 | AstraZeneca AB; Amylin Ohio LLC | CDE ↗ |
No verified English name 1 records · Latest accepted 2021/03/12
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHL2100085 | Import | 2021/03/12 | AstraZeneca AB | CDE ↗ |
No verified English name 1 records · Latest accepted 2021/01/22
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2100089 | Supplement | 2021/01/22 | AstraZeneca AB | CDE ↗ |
Changes in the last 90 days
63 events from 2026/08/14 to 2026/11/11. CDE data as of 2026/11/11 06:42; NMPA data as of 2026/11/10 18:31.
This source was last successfully updated at 2026/11/10 18:31; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Accepted: 44 applicationsNo longer listed under review: 19 applications
- 2026/11/09Accepted
No verified English name
JXSL2600309
Fact date: 2026/11/09 · Site observation date: 2026/11/10
View source ↗ - 2026/11/06No longer listed under review
No verified English name
JXSL2600223
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2026/08/24
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/11/06No longer listed under review
No verified English name
JXSB2600193
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2026/10/15
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/11/06No longer listed under review
No verified English name
JXHL2600362
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2026/08/24
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/11/06No longer listed under review
No verified English name
JXHL2600361
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2026/08/24
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/11/06No longer listed under review
Osimertinib Mesylate Tablets
JXHB2600125
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2026/09/04
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/11/06No longer listed under review
Osimertinib Mesylate Tablets
JXHB2600124
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2026/09/04
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/11/06Accepted
No verified English name
JYSB2600312
Fact date: 2026/11/06 · Site observation date: 2026/11/07
View source ↗ - 2026/11/06Accepted
No verified English name
JXHB2600164
Fact date: 2026/11/06 · Site observation date: 2026/11/07
View source ↗ - 2026/11/06Accepted
No verified English name
JXHB2600163
Fact date: 2026/11/06 · Site observation date: 2026/11/07
View source ↗ - 2026/11/06Accepted
No verified English name
JXHB2600162
Fact date: 2026/11/06 · Site observation date: 2026/11/07
View source ↗ - 2026/11/03Accepted
No verified English name
JXSL2600294
Fact date: 2026/11/03 · Site observation date: 2026/11/04
View source ↗ - 2026/11/03Accepted
No verified English name
JXSL2600293
Fact date: 2026/11/03 · Site observation date: 2026/11/04
View source ↗ - 2026/11/03Accepted
No verified English name
JXSL2600292
Fact date: 2026/11/03 · Site observation date: 2026/11/04
View source ↗ - 2026/11/03Accepted
No verified English name
JXHL2600482
Fact date: 2026/11/03 · Site observation date: 2026/11/04
View source ↗ - 2026/11/03Accepted
No verified English name
JXHL2600481
Fact date: 2026/11/03 · Site observation date: 2026/11/04
View source ↗ - 2026/10/31No longer listed under review
No verified English name
JXSB2600156
Fact date: 2026/10/31 · Site observation date: 2026/10/31
Accepted: 2026/08/20
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/31No longer listed under review
No verified English name
JXSB2600155
Fact date: 2026/10/31 · Site observation date: 2026/10/31
Accepted: 2026/08/20
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/30Accepted
No verified English name
JXSS2600101
Fact date: 2026/10/30 · Site observation date: 2026/10/31
View source ↗ - 2026/10/30Accepted
No verified English name
JXSS2600100
Fact date: 2026/10/30 · Site observation date: 2026/10/31
View source ↗ - 2026/10/28Accepted
No verified English name
JXSL2600288
Fact date: 2026/10/28 · Site observation date: 2026/10/29
View source ↗ - 2026/10/28Accepted
No verified English name
JXSL2600287
Fact date: 2026/10/28 · Site observation date: 2026/10/29
View source ↗ - 2026/10/28Accepted
No verified English name
JXSL2600286
Fact date: 2026/10/28 · Site observation date: 2026/10/29
View source ↗ - 2026/10/27No longer listed under review
Osimertinib Mesylate Tablets
JXHL2600355
Fact date: 2026/10/27 · Site observation date: 2026/10/27
Accepted: 2026/08/19
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/27No longer listed under review
Osimertinib Mesylate Tablets
JXHL2600354
Fact date: 2026/10/27 · Site observation date: 2026/10/27
Accepted: 2026/08/19
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/27No longer listed under review
No verified English name
JXHB2600121
Fact date: 2026/10/27 · Site observation date: 2026/10/27
Accepted: 2026/09/01
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/27No longer listed under review
No verified English name
JXHB2600120
Fact date: 2026/10/27 · Site observation date: 2026/10/27
Accepted: 2026/09/01
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/27No longer listed under review
No verified English name
JXHB2600119
Fact date: 2026/10/27 · Site observation date: 2026/10/27
Accepted: 2026/09/01
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/27No longer listed under review
No verified English name
JXHB2600118
Fact date: 2026/10/27 · Site observation date: 2026/10/27
Accepted: 2026/09/01
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/24No longer listed under review
No verified English name
JXSB2600158
Fact date: 2026/10/24 · Site observation date: 2026/10/24
Accepted: 2026/08/25
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/23No longer listed under review
Olaparib Tablets
JYHB2600193
Fact date: 2026/10/23 · Site observation date: 2026/10/23
Accepted: 2026/03/24
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/23No longer listed under review
Olaparib Tablets
JYHB2600192
Fact date: 2026/10/23 · Site observation date: 2026/10/23
Accepted: 2026/03/24
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ - 2026/10/23No longer listed under review
No verified English name
JTS2600149
Fact date: 2026/10/23 · Site observation date: 2026/10/23
Accepted: 2026/09/21
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/10/23 (approval no.: —; approval date: 2026/10/21) · NMPA source · row 163
NMPA · Table row 163 ↗ View source ↗ - 2026/10/23No longer listed under review
No verified English name
JTS2600148
Fact date: 2026/10/23 · Site observation date: 2026/10/23
Accepted: 2026/09/21
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/10/23 (approval no.: —; approval date: 2026/10/21) · NMPA source · row 162
NMPA · Table row 162 ↗ View source ↗ - 2026/10/23Accepted
No verified English name
JXSL2600284
Fact date: 2026/10/23 · Site observation date: 2026/10/24
View source ↗ - 2026/10/23Accepted
No verified English name
JXSL2600283
Fact date: 2026/10/23 · Site observation date: 2026/10/24
View source ↗ - 2026/10/21Accepted
No verified English name
JXSB2600197
Fact date: 2026/10/21 · Site observation date: 2026/10/22
View source ↗ - 2026/10/21Accepted
No verified English name
JXSB2600196
Fact date: 2026/10/21 · Site observation date: 2026/10/22
View source ↗ - 2026/10/15Accepted
No verified English name
JXSB2600193
Fact date: 2026/10/15 · Site observation date: 2026/10/22
View source ↗ - 2026/10/12Accepted
No verified English name
JYHB2600546
Fact date: 2026/10/12 · Site observation date: 2026/10/22
View source ↗ - 2026/10/08Accepted
No verified English name
JXSL2600264
Fact date: 2026/10/08 · Site observation date: 2026/10/22
View source ↗ - 2026/10/08Accepted
No verified English name
JXSL2600263
Fact date: 2026/10/08 · Site observation date: 2026/10/22
View source ↗ - 2026/10/08Accepted
No verified English name
JXHL2600437
Fact date: 2026/10/08 · Site observation date: 2026/10/22
View source ↗ - 2026/10/08Accepted
No verified English name
JXHL2600436
Fact date: 2026/10/08 · Site observation date: 2026/10/22
View source ↗ - 2026/09/24Accepted
No verified English name
JXHL2600417
Fact date: 2026/09/24 · Site observation date: 2026/10/22
View source ↗ - 2026/09/21Accepted
No verified English name
JTS2600149
Fact date: 2026/09/21 · Site observation date: 2026/10/22
View source ↗ - 2026/09/21Accepted
No verified English name
JTS2600148
Fact date: 2026/09/21 · Site observation date: 2026/10/22
View source ↗ - 2026/09/08Accepted
No verified English name
JXSB2600172
Fact date: 2026/09/08 · Site observation date: 2026/10/22
View source ↗ - 2026/09/07Accepted
No verified English name
JXSB2600171
Fact date: 2026/09/07 · Site observation date: 2026/10/22
View source ↗ - 2026/09/04Accepted
Osimertinib Mesylate Tablets
JXHB2600125
Fact date: 2026/09/04 · Site observation date: 2026/10/22
View source ↗ - 2026/09/04Accepted
Osimertinib Mesylate Tablets
JXHB2600124
Fact date: 2026/09/04 · Site observation date: 2026/10/22
View source ↗ - 2026/09/01Accepted
No verified English name
JXHB2600121
Fact date: 2026/09/01 · Site observation date: 2026/10/22
View source ↗ - 2026/09/01Accepted
No verified English name
JXHB2600120
Fact date: 2026/09/01 · Site observation date: 2026/10/22
View source ↗ - 2026/09/01Accepted
No verified English name
JXHB2600119
Fact date: 2026/09/01 · Site observation date: 2026/10/22
View source ↗ - 2026/09/01Accepted
No verified English name
JXHB2600118
Fact date: 2026/09/01 · Site observation date: 2026/10/22
View source ↗ - 2026/08/25Accepted
No verified English name
JXSB2600158
Fact date: 2026/08/25 · Site observation date: 2026/10/22
View source ↗ - 2026/08/24Accepted
No verified English name
JXSL2600223
Fact date: 2026/08/24 · Site observation date: 2026/10/22
View source ↗ - 2026/08/24Accepted
No verified English name
JXHL2600362
Fact date: 2026/08/24 · Site observation date: 2026/10/22
View source ↗ - 2026/08/24Accepted
No verified English name
JXHL2600361
Fact date: 2026/08/24 · Site observation date: 2026/10/22
View source ↗ - 2026/08/20Accepted
No verified English name
JXSB2600156
Fact date: 2026/08/20 · Site observation date: 2026/10/22
View source ↗ - 2026/08/20Accepted
No verified English name
JXSB2600155
Fact date: 2026/08/20 · Site observation date: 2026/10/22
View source ↗ - 2026/08/19Accepted
Osimertinib Mesylate Tablets
JXHL2600355
Fact date: 2026/08/19 · Site observation date: 2026/10/22
View source ↗ - 2026/08/19Accepted
Osimertinib Mesylate Tablets
JXHL2600354
Fact date: 2026/08/19 · Site observation date: 2026/10/22
View source ↗
Under review
42 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/11 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No verified English name | JXSL2600309 | Import | 2026/11/09 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd | CDE ↗ |
| No verified English name | JYSB2600312 | Supplement | 2026/11/06 | AstraZeneca AB; Amgen Manufacturing Limited LLC | CDE ↗ |
| No verified English name | JXHB2600164 | Supplement | 2026/11/06 | AstraZeneca AB; Patheon France | CDE ↗ |
| No verified English name | JXHB2600163 | Supplement | 2026/11/06 | AstraZeneca AB; Patheon France | CDE ↗ |
| No verified English name | JXHB2600162 | Supplement | 2026/11/06 | AstraZeneca AB; Patheon France | CDE ↗ |
| No verified English name | JXSL2600294 | Import | 2026/11/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSL2600293 | Import | 2026/11/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSL2600292 | Import | 2026/11/03 | AstraZeneca AB; AstraZeneca Global ll&U (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXHL2600482 | Import | 2026/11/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXHL2600481 | Import | 2026/11/03 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSS2600101 | Import | 2026/10/30 | AstraZeneca AB; Amgen Manufacturing Limited LLC; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSS2600100 | Import | 2026/10/30 | AstraZeneca AB; Amgen Manufacturing Limited LLC; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSL2600288 | Import | 2026/10/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSL2600287 | Import | 2026/10/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSL2600286 | Import | 2026/10/28 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSL2600284 | Import | 2026/10/23 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSL2600283 | Import | 2026/10/23 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSB2600197 | Supplement | 2026/10/21 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| No verified English name | JXSB2600196 | Supplement | 2026/10/21 | AstraZeneca AB; AstraZeneca Nijmegen B.V. | CDE ↗ |
| No verified English name | JYHB2600546 | Supplement | 2026/10/12 | AstraZeneca AB | CDE ↗ |
| No verified English name | JXSL2600264 | Import | 2026/10/08 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSL2600263 | Import | 2026/10/08 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXHL2600437 | Import | 2026/10/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXHL2600436 | Import | 2026/10/08 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXHL2600417 | Import | 2026/09/24 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSB2600172 | Supplement | 2026/09/08 | AstraZeneca AB; Simtra Deutschland GmbH | CDE ↗ |
| Ticagrelor Tablets | JYHB2600465 | Supplement | 2026/08/13 | AstraZeneca AB | CDE ↗ |
| Ticagrelor Tablets | JYHB2600464 | Supplement | 2026/08/13 | AstraZeneca AB | CDE ↗ |
| No verified English name | JYHB2600463 | Supplement | 2026/08/13 | AstraZeneca AB | CDE ↗ |
| Osimertinib Mesylate Tablets | JYHB2600457 | Supplement | 2026/08/12 | AstraZeneca AB | CDE ↗ |
| Osimertinib Mesylate Tablets | JYHB2600456 | Supplement | 2026/08/12 | AstraZeneca AB | CDE ↗ |
| No verified English name | JXSS2600055 | Import | 2026/06/26 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXHS2600026 | Import | 2026/02/13 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXHS2600025 | Import | 2026/02/13 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JYHB2600093 | Supplement | 2026/02/10 | AstraZeneca AB | CDE ↗ |
| No verified English name | JXHS2600023 | Import | 2026/02/10 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JYHB2600082 | Supplement | 2026/02/05 | AstraZeneca AB; AndersonBrecon Inc.; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| No verified English name | JYHB2600081 | Supplement | 2026/02/05 | AstraZeneca AB; AndersonBrecon Inc.; AstraZeneca Pharmaceuticals LP | CDE ↗ |
| No verified English name | JYHB2500517 | Supplement | 2025/10/14 | AstraZeneca AB | CDE ↗ |
| No verified English name | JXHS2500104 | Import | 2025/09/17 | AstraZeneca AB; ASTRAZENECA DUNKERQUE PRODUCTION; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSS2500109 | Import | 2025/08/20 | AstraZeneca AB; AstraZeneca Nijmegen B.V.; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JYHB2400685 | Supplement | 2024/12/27 | AstraZeneca AB; ASTRAZENECA DUNKERQUE PRODUCTION; Bespak HC Limited | CDE ↗ |
Catalogue holder records
26 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/11 06:38. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Olaparib Tablets | AstraZeneca AB | AbbVie Deutschland GmbH & Co. KG | H20180049 | 2018/08/22 | Imported originator drug | CDE ↗ |
| Olaparib Tablets | AstraZeneca AB | AbbVie Deutschland GmbH & Co. KG | H20180048 | 2018/08/22 | Imported originator drug | CDE ↗ |
| Ticagrelor Tablets | AstraZeneca AB | Astrazeneca AB | H20171037 | 2017/06/27 | Imported originator drug | CDE ↗ |
| Saxagliptin and Metformin Hydrochloride Sustained-release Tablets | AstraZeneca AB | AstraZeneca Pharmaceuticals LP | H20170251;H20170252;H20171049 | 2017/05/18 | Imported originator drug | CDE ↗ |
| Saxagliptin and Metformin Hydrochloride Sustained-release Tablets | AstraZeneca AB | AstraZeneca Pharmaceuticals LP | H20170255;H20170256;H20171051 | 2017/05/18 | Imported originator drug | CDE ↗ |
| Osimertinib Mesylate Tablets | AstraZeneca AB | AstraZeneca AB | H20170167 | 2017/03/22 | Imported originator drug | CDE ↗ |
| Osimertinib Mesylate Tablets | AstraZeneca AB | AstraZeneca AB | H20170166 | 2017/03/22 | Imported originator drug | CDE ↗ |
| Dapagliflozin Tablets | AstraZeneca AB | AstraZeneca Pharmaceuticals LP | H20170119;H20170120;H20170206 | 2017/03/10 | Imported originator drug | CDE ↗ |
| Dapagliflozin Tablets | AstraZeneca AB | AstraZeneca Pharmaceuticals LP | H20170117;H20170118;H20170205 | 2017/03/10 | Imported originator drug | CDE ↗ |
| Ticagrelor Tablets | AstraZeneca AB | Astrazeneca AB | H20171079 | 2012/11/22 | Imported originator drug | CDE ↗ |
| No verified English name | AstraZeneca AB | AstraZeneca AB | H20160447 | 2011/12/12 | Imported originator drug | CDE ↗ |
| Saxagliptin Tablets | AstraZeneca AB | AstraZeneca Pharmaceuticals LP | H20160089;H20160090 | 2011/05/05 | Imported originator drug | CDE ↗ |
| Fulvestrant Injection | AstraZeneca AB | Vetter Pharma-Fertigung GmbH & Co. KG | H20171199 | 2010/06/04 | Imported originator drug | CDE ↗ |
| Exenatide Injection | AstraZeneca AB | Baxter Pharmaceutical Solutions LLC | H20140822 | 2009/05/08 | Imported originator drug | CDE ↗ |
| Exenatide Injection | AstraZeneca AB | Baxter Pharmaceutical Solutions LLC | H20140821 | 2009/05/08 | Imported originator drug | CDE ↗ |
| Metoprolol Succinate Sustained-release Tablets | AstraZeneca AB | Astrazeneca AB | H20140780 | 2005/04/20 | Imported originator drug | CDE ↗ |
| Metoprolol Succinate Sustained-release Tablets | AstraZeneca AB | AstraZeneca AB | H20140779 | 2005/04/20 | Imported originator drug | CDE ↗ |
| No verified English name | AstraZeneca AB | AstraZeneca UK Limited | H20140471 | 2004/12/06 | Imported originator drug | CDE ↗ |
| No verified English name | AstraZeneca AB | AstraZeneca AB | H20140457 | 2004/11/17 | Imported originator drug | CDE ↗ |
| No verified English name | AstraZeneca AB | AstraZeneca AB | H20140458 | 2004/11/17 | Imported originator drug | CDE ↗ |
| No verified English name | AstraZeneca AB | AstraZeneca AB | H20140459 | 2004/11/17 | Imported originator drug | CDE ↗ |
| Esomeprazole Magnesium Gastro-Resistant Tablets | AstraZeneca AB | Astrazeneca AB | H20181003 | 2002/10/16 | Imported originator drug | CDE ↗ |
| Esomeprazole Magnesium Gastro-Resistant Tablets | AstraZeneca AB | Astrazeneca AB | H20181004 | 2002/10/16 | Imported originator drug | CDE ↗ |
| Ropivacaine hydrochloride injection | AstraZeneca AB | AstraZeneca AB | H20140764 | 1998/12/17 | Imported originator drug | CDE ↗ |
| Ropivacaine hydrochloride injection | AstraZeneca AB | AstraZeneca AB | H20140763 | 1998/12/17 | Imported originator drug | CDE ↗ |
| No verified English name | AstraZeneca AB | AstraZeneca AB | H20140108 | 1997/06/20 | Imported originator drug | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
20 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/11 06:40.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No verified English name | AstraZeneca AB | Y20230000568 | A | 2025/07/22 | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20210000736 | A | 2026/05/20 | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20210000271 | A | 2026/08/21 | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20210000149 | A | 2023/04/06 | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20190009941 | A | — | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20190009940 | A | — | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20190009931 | A | — | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20190009213 | A | — | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20190009212 | A | — | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20190009210 | A | — | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20190009209 | A | — | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20190009177 | A | 2024/09/03 | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20180001210 | I | 2018/11/13 | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20180000947 | I | 2018/08/22 | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20170002331 | A | — | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20170002330 | A | 2024/08/07 | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20170002043 | A | 2024/08/08 | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20170001948 | A | 2024/09/24 | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20170001947 | A | 2024/09/24 | CDE ↗ |
| No verified English name | AstraZeneca AB | Y20170001491 | A | 2024/09/25 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
109 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/11 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No verified English name | JYHB2600547 | Supplement | 2026/10/12 | AstraZeneca Pty Ltd; AstraZeneca AB | CDE ↗ |
| No verified English name | JTH2600206 | Not stated by source | 2026/10/09 | Bespak HC Limited; AstraZeneca AB; A Si Li Kang Pharmaceutical (Qingdao) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600202 | Not stated by source | 2026/09/23 | AstraZeneca; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600201 | Not stated by source | 2026/09/23 | S.A Ajinomoto Omnichem N.V.; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JXHS2600093 | Import | 2026/08/17 | AstraZeneca Pty Ltd; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXHS2600085 | Import | 2026/07/30 | AstraZeneca UK Limited; AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXHS2600084 | Import | 2026/07/30 | AstraZeneca UK Limited; AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JTH2600117 | Not stated by source | 2026/06/23 | Bespak HC Limited; AstraZeneca AB; A Si Li Kang Pharmaceutical (Qingdao) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JYHB2600309 | Supplement | 2026/06/05 | AstraZeneca Pty Ltd; AstraZeneca AB | CDE ↗ |
| No verified English name | JXSB2600077 | Supplement | 2026/05/29 | Medlmmune LLC; Catalent Indiana LLC; AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG | CDE ↗ |
| No verified English name | JTH2600093 | Not stated by source | 2026/05/08 | Bespak HC Limited; AstraZeneca AB; A Si Li Kang Pharmaceutical (Qingdao) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JYHB2600229 | Supplement | 2026/04/23 | AstraZeneca UK Limited; AstraZeneca AB | CDE ↗ |
| No verified English name | JYHB2600228 | Supplement | 2026/04/23 | AstraZeneca UK Limited; AstraZeneca AB | CDE ↗ |
| No verified English name | JTS2600028 | Not stated by source | 2026/02/13 | AstraZeneca Pharmaceuticals LP; AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JYHB2600092 | Supplement | 2026/02/10 | AstraZeneca Pty Ltd; AstraZeneca AB | CDE ↗ |
| No verified English name | JXHS2600022 | Import | 2026/02/10 | AstraZeneca Pty Ltd; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JTH2500143 | Not stated by source | 2025/09/22 | Bespak HC Limited; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JYSB2500227 | Supplement | 2025/09/19 | AstraZeneca UK Limited; AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG | CDE ↗ |
| No verified English name | JYSB2500226 | Supplement | 2025/09/19 | AstraZeneca UK Limited; AstraZeneca AB; Vetter Pharma-Fertigung GmbH & Co. KG | CDE ↗ |
| No verified English name | JXSB2500091 | Supplement | 2025/08/19 | Medlmmune LLC; Catalent Indiana LLC; AstraZeneca AB | CDE ↗ |
| No verified English name | JTH2500063 | Not stated by source | 2025/04/08 | Minakem High Potent SA; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| Ropivacaine hydrochloride injection | JYHB2500189 | Supplement | 2025/03/29 | Aspen Pharmacare Australia Pty Ltd; AstraZeneca AB | CDE ↗ |
| Ropivacaine hydrochloride injection | JYHB2500188 | Supplement | 2025/03/29 | Aspen Pharmacare Australia Pty Ltd; AstraZeneca AB | CDE ↗ |
| Ropivacaine hydrochloride injection | JYHB2500187 | Supplement | 2025/03/29 | Aspen Pharmacare Australia Pty Ltd; AstraZeneca AB | CDE ↗ |
| No verified English name | JXSS2500038 | Import | 2025/03/28 | AstraZeneca UK Limited; Catalent Indiana LLC; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSS2500037 | Import | 2025/03/28 | AstraZeneca UK Limited; Catalent Indiana LLC; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSS2500028 | Import | 2025/03/22 | AstraZeneca UK Limited; Catalent Indiana LLC; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSS2500027 | Import | 2025/03/22 | AstraZeneca UK Limited; Catalent Indiana LLC; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JTH2500053 | Not stated by source | 2025/03/21 | AstraZeneca Dunkerque Production; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JXSS2500018 | Import | 2025/02/25 | AstraZeneca UK Limited; Catalent Indiana LLC; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSS2500017 | Import | 2025/02/25 | AstraZeneca UK Limited; Catalent Indiana LLC; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSS2500014 | Import | 2025/02/21 | AstraZeneca UK Limited; Catalent Indiana LLC; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXSS2500013 | Import | 2025/02/21 | AstraZeneca UK Limited; Catalent Indiana LLC; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JYSB2500039 | Supplement | 2025/02/15 | AstraZeneca UK Limited; Catalent Indiana LLC; AstraZeneca AB | CDE ↗ |
| No verified English name | JYSB2500038 | Supplement | 2025/02/15 | AstraZeneca UK Limited; Catalent Indiana LLC; AstraZeneca AB | CDE ↗ |
| Ropivacaine hydrochloride injection | JYHB2400555 | Supplement | 2024/10/18 | Aspen Pharmacare Australia Pty Ltd; AstraZeneca AB; Aspen Notre Dame de Bondeville | CDE ↗ |
| Ropivacaine hydrochloride injection | JYHB2400554 | Supplement | 2024/10/18 | Aspen Pharmacare Australia Pty Ltd; AstraZeneca AB; Aspen Notre Dame de Bondeville | CDE ↗ |
| No verified English name | JTS2400113 | Not stated by source | 2024/09/27 | AstraZeneca Pharmaceuticals LP; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2400112 | Not stated by source | 2024/09/27 | AstraZeneca Pharmaceuticals LP; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2400111 | Not stated by source | 2024/09/27 | AstraZeneca Pharmaceuticals LP; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| Ropivacaine hydrochloride injection | JYHZ2400261 | Import re-registration | 2024/09/26 | Aspen Pharmacare Australia Pty Ltd; AstraZeneca AB | CDE ↗ |
| Ropivacaine hydrochloride injection | JYHZ2400260 | Import re-registration | 2024/09/26 | Aspen Pharmacare Australia Pty Ltd; AstraZeneca AB | CDE ↗ |
| Ropivacaine hydrochloride injection | JYHZ2400259 | Import re-registration | 2024/09/26 | Aspen Pharmacare Australia Pty Ltd; AstraZeneca AB | CDE ↗ |
| No verified English name | JTS2400098 | Not stated by source | 2024/09/21 | AstraZeneca Nijmegen B.V.; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JXHS2400059 | Import | 2024/08/28 | AstraZeneca Pty Ltd; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JTS2400079 | Not stated by source | 2024/08/20 | Amgen Manufacturing Limited LLC; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2400078 | Not stated by source | 2024/08/20 | Amgen Manufacturing Limited LLC; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2400134 | Not stated by source | 2024/08/09 | Vetter Pharma-Fertigung GmbH & Co. KG; AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JXHS2400047 | Import | 2024/07/05 | AstraZeneca Pty Ltd; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JTS2400043 | Not stated by source | 2024/06/12 | Immunex Rhode Island Corporation（ARI）; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2400042 | Not stated by source | 2024/06/12 | Amgen Manufacturing Ltd（AML）; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2400041 | Not stated by source | 2024/06/12 | Amgen Manufacturing Ltd（AML）; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2400033 | Not stated by source | 2024/04/13 | Vetter Pharma-Fertigung GmbH & Co. KG; AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2400032 | Not stated by source | 2024/04/13 | Vetter Pharma-Fertigung GmbH & Co. KG; AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2400031 | Not stated by source | 2024/04/13 | Boehringer Ingelheim Pharma; AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2300247 | Not stated by source | 2023/10/20 | Minakem High Potent SA; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2300246 | Not stated by source | 2023/10/20 | AstraZeneca UK Limited; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JXHS2300096 | Import | 2023/10/10 | AstraZeneca UK Limited; AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXHS2300095 | Import | 2023/10/10 | AstraZeneca UK Limited; AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. | CDE ↗ |
| No verified English name | JTH2300230 | Not stated by source | 2023/09/22 | Ajinomoto Omnichem N.V.; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2300221 | Not stated by source | 2023/09/13 | AstraZeneca UK Limited; AstraZeneca AB; A Si Li Kang Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JXHS2300077 | Import | 2023/08/17 | AstraZeneca Pty Ltd; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JXHS2300076 | Import | 2023/08/17 | AstraZeneca Pty Ltd; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JYSB2300122 | Supplement | 2023/07/14 | AstraZeneca UK Limited; Catalent Indiana LLC; AstraZeneca AB | CDE ↗ |
| No verified English name | JYSB2300121 | Supplement | 2023/07/14 | AstraZeneca UK Limited; Catalent Indiana LLC; AstraZeneca AB | CDE ↗ |
| No verified English name | JTH2300165 | Not stated by source | 2023/07/06 | Vetter Pharma-Fertigung GmbH & Co. KG; AstraZeneca AB; A Si Li Kang Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2300013 | Not stated by source | 2023/03/17 | AstraZeneca Pharmaceuticals LP Frederick Manufacturing Center; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| Ropivacaine hydrochloride injection | JYHB2300140 | Supplement | 2023/02/23 | Aspen Pharmacare Australia Pty Ltd; AstraZeneca AB | CDE ↗ |
| Ropivacaine hydrochloride injection | JYHB2300139 | Supplement | 2023/02/23 | Aspen Pharmacare Australia Pty Ltd; AstraZeneca AB | CDE ↗ |
| Ropivacaine hydrochloride injection | JYHB2300138 | Supplement | 2023/02/23 | Aspen Pharmacare Australia Pty Ltd; AstraZeneca AB | CDE ↗ |
| Ropivacaine hydrochloride injection | JYHB2300137 | Supplement | 2023/02/23 | Aspen Pharmacare Australia Pty Ltd; AstraZeneca AB | CDE ↗ |
| No verified English name | JXHS2200121 | Import | 2022/12/23 | AstraZeneca Pty Ltd; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JTS2200067 | Not stated by source | 2022/08/25 | Patheon Manufacturing Services LLC; AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2200066 | Not stated by source | 2022/08/25 | Patheon Manufacturing Services LLC; AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| Esomeprazole Magnesium Gastro-Resistant Tablets | JYHB2200391 | Supplement | 2022/07/25 | AstraZeneca UK Limited; AstraZeneca AB | CDE ↗ |
| Esomeprazole Magnesium Gastro-Resistant Tablets | JYHB2200390 | Supplement | 2022/07/25 | AstraZeneca UK Limited; AstraZeneca AB | CDE ↗ |
| Esomeprazole Sodium for Injection | JYHB2200345 | Supplement | 2022/07/07 | AstraZeneca UK Limited; AstraZeneca AB | CDE ↗ |
| Esomeprazole Magnesium Gastro-Resistant Tablets | JYHZ2200186 | Import re-registration | 2022/07/05 | AstraZeneca UK Limited; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| Esomeprazole Magnesium Gastro-Resistant Tablets | JYHZ2200185 | Import re-registration | 2022/07/05 | AstraZeneca UK Limited; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| Esomeprazole Magnesium Gastro-Resistant Tablets | JYHZ2200184 | Import re-registration | 2022/07/05 | AstraZeneca UK Limited; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| Esomeprazole Magnesium Gastro-Resistant Tablets | JYHZ2200183 | Import re-registration | 2022/07/05 | AstraZeneca UK Limited; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| No verified English name | JYHZ2200155 | Import re-registration | 2022/06/17 | AstraZeneca Pty Ltd; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| No verified English name | JYHZ2200154 | Import re-registration | 2022/06/17 | AstraZeneca Pty Ltd; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| No verified English name | JYHZ2200153 | Import re-registration | 2022/06/17 | AstraZeneca Pty Ltd; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| No verified English name | JYHZ2200152 | Import re-registration | 2022/06/17 | AstraZeneca Pty Ltd; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| No verified English name | JTS2200038 | Not stated by source | 2022/06/13 | Patheon Manufacturing Services LLC; AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2200037 | Not stated by source | 2022/06/13 | Patheon Manufacturing Services LLC; AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2200036 | Not stated by source | 2022/06/13 | AstraZeneca Pharmaceuticals LP Frederick Manufacturing Center; AstraZeneca AB; A Si Li Kang Quan Qiu Research and Development (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| No verified English name | JYHB2200220 | Supplement | 2022/04/18 | AstraZeneca Pty Ltd; AstraZeneca AB | CDE ↗ |
| No verified English name | JYHB2200219 | Supplement | 2022/04/18 | AstraZeneca Pty Ltd; AstraZeneca AB | CDE ↗ |
| No verified English name | JXHS2101107 | Import | 2022/01/05 | AstraZeneca Pty Ltd; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. | CDE ↗ |
| No verified English name | JYHB2101495 | Supplement | 2021/11/01 | AstraZeneca Pty Ltd; AstraZeneca AB | CDE ↗ |
| No verified English name | JYHB2101494 | Supplement | 2021/11/01 | AstraZeneca Pty Ltd; AstraZeneca AB | CDE ↗ |
| No verified English name | JYHB2101493 | Supplement | 2021/11/01 | AstraZeneca Pty Ltd; AstraZeneca AB | CDE ↗ |
| No verified English name | JYHB2101492 | Supplement | 2021/11/01 | AstraZeneca Pty Ltd; AstraZeneca AB | CDE ↗ |
| Dapagliflozin And Metformin Hydrochloride Extended-Release Tablets | JTH2100635 | Not stated by source | 2021/08/31 | AstraZeneca Pharmaceuticals LP; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| Dapagliflozin And Metformin Hydrochloride Extended-Release Tablets | JTH2100634 | Not stated by source | 2021/08/31 | AstraZeneca Pharmaceuticals LP; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| Dapagliflozin And Metformin Hydrochloride Extended-Release Tablets | JTH2100633 | Not stated by source | 2021/08/31 | AstraZeneca Pharmaceuticals LP; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| Dapagliflozin And Metformin Hydrochloride Extended-Release Tablets | JTH2100632 | Not stated by source | 2021/08/31 | AstraZeneca Pharmaceuticals LP; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| Dapagliflozin And Metformin Hydrochloride Extended-Release Tablets | JTH2100631 | Not stated by source | 2021/08/31 | AstraZeneca Pharmaceuticals LP; AstraZeneca AB; A Si Li Kang Investment (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| Esomeprazole Magnesium Gastro-Resistant Tablets | JYHB2101345 | Supplement | 2021/08/24 | AstraZeneca UK Limited; AstraZeneca AB | CDE ↗ |
| Esomeprazole Magnesium Gastro-Resistant Tablets | JYHB2101344 | Supplement | 2021/08/24 | AstraZeneca UK Limited; AstraZeneca AB | CDE ↗ |
| Esomeprazole Magnesium Gastro-Resistant Tablets | JYHB2101343 | Supplement | 2021/08/24 | AstraZeneca UK Limited; AstraZeneca AB | CDE ↗ |
| Esomeprazole Magnesium Gastro-Resistant Tablets | JYHB2101342 | Supplement | 2021/08/24 | AstraZeneca UK Limited; AstraZeneca AB | CDE ↗ |
| Budesonide Nasal Spray | JYHB2101132 | Supplement | 2021/05/25 | McNeil Sweden AB; AstraZeneca AB | CDE ↗ |
| Budesonide Nasal Spray | JYHB2101131 | Supplement | 2021/05/25 | McNeil Sweden AB; AstraZeneca AB | CDE ↗ |
| Esomeprazole Sodium for Injection | JYHZ2100507 | Import re-registration | 2021/03/24 | AstraZeneca UK Limited; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| Esomeprazole Sodium for Injection | JYHZ2100506 | Import re-registration | 2021/03/24 | AstraZeneca UK Limited; AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd | CDE ↗ |
| No verified English name | JTS2100018 | Not stated by source | 2021/02/05 | Symbiosis Pharmaceuticals Services; AstraZeneca AB; Shenzhen Kang Tai Bio Zhi Pin Co., Ltd. romanized | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/11 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/11 06:38
- Full API register
- Last successful update: 2026/11/11 06:40
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31 · Current coverage may be incomplete
First index-page publication dates: — to —; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drug names use verified official English names only. Missing names are shown as No verified English name, linking to a Chinese page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized. Original statutory reference numbers are the sole visible Chinese exception.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Chinese free text is not displayed; use the source links or source-name columns in CSV exports.